Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
12 "Young Rok Do"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Hematologic malignancy
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
Cancer Res Treat. 2024;56(2):681-687.   Published online November 10, 2023
DOI: https://doi.org/10.4143/crt.2023.1042
AbstractAbstract PDFPubReaderePub
Purpose
Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods
Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results
The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion
In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.

Citations

Citations to this article as recorded by  
  • An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma
    Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
    Expert Opinion on Biological Therapy.2025; 25(1): 9.     CrossRef
  • Pembrolizumab

    Reactions Weekly.2024; 2025(1): 390.     CrossRef
  • 3,561 View
  • 202 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(2):684-692.   Published online January 2, 2023
DOI: https://doi.org/10.4143/crt.2022.1434
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by  
  • Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
    Journal of Cancer Research Updates.2024; 13: 1.     CrossRef
  • Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
    L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
    Bone Marrow Transplantation.2024; 59(6): 838.     CrossRef
  • Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
    Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
    Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
    Clinical and Experimental Medicine.2023; 23(8): 4219.     CrossRef
  • 5,262 View
  • 200 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(1):325-333.   Published online April 22, 2022
DOI: https://doi.org/10.4143/crt.2022.008
AbstractAbstract PDFPubReaderePub
Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by  
  • PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
    Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
    Cancer Cell International.2025;[Epub]     CrossRef
  • Recent advances in cellular immunotherapy for lymphoid malignancies
    Haerim Chung, Hyunsoo Cho
    Blood Research.2023; 58(4): 166.     CrossRef
  • Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
    Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
    Biomedicine & Pharmacotherapy.2022; 153: 113341.     CrossRef
  • 7,076 View
  • 348 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)
Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won
Cancer Res Treat. 2023;55(1):304-313.   Published online March 30, 2022
DOI: https://doi.org/10.4143/crt.2022.004
AbstractAbstract PDFPubReaderePub
Purpose
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.
Materials and Methods
Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg/kg/day, intravenously) administered on days –7, –6, and –5, etoposide (400 mg/m2 intravenously) on days –5 and –4, and melphalan (50 mg/m2/day intravenously) on days –3 and –2. The BuCE regimen was comprised of busulfan (3.2 mg/kg/day intravenously) on days –7, –6, and –5, etoposide (400 mg/m2/day intravenously) on days –5 and –4, and cyclophosphamide (50 mg/kg/day intravenously) on days –3 and –2. The primary endpoint was 2-year progression-free survival (PFS).
Results
Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.
Conclusion
There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.

Citations

Citations to this article as recorded by  
  • CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-match
    Tao Wang, Ping Liu, Lili Xu, Lei Gao, Xiong Ni, Gusheng Tang, Li Chen, Jie Chen, Libing Wang, Yang Wang, Weijia Fu, Wenqin Yue, Na Liu, Ruobing Li, Guihua Lu, Yanrong Luo, Jianmin Yang
    Annals of Hematology.2024; 103(2): 575.     CrossRef
  • 5,690 View
  • 235 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2022;54(4):1268-1277.   Published online December 30, 2021
DOI: https://doi.org/10.4143/crt.2021.1168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.
  • 7,532 View
  • 295 Download
  • 1 Web of Science
Close layer
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh
Cancer Res Treat. 2015;47(2):173-181.   Published online October 28, 2014
DOI: https://doi.org/10.4143/crt.2014.055
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by  
  • Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
    Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
    Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
    Cancer Medicine.2019; 8(3): 874.     CrossRef
  • ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
    Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
    Leukemia & Lymphoma.2019; 60(10): 2532.     CrossRef
  • Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
    Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
    International Journal of Hematology.2018; 107(4): 395.     CrossRef
  • Recent advances in treating extra-ocular lymphomas
    Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
    Expert Review of Ophthalmology.2018; 13(4): 205.     CrossRef
  • The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
    Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
    Blood Research.2017; 52(1): 3.     CrossRef
  • Primary lymphomas in the gastrointestinal tract
    Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
    Journal of Digestive Diseases.2015; 16(4): 169.     CrossRef
  • 15,887 View
  • 142 Download
  • 10 Web of Science
  • 7 Crossref
Close layer
Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement
Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Deok-Hwan Yang, Hyeoung-Joon Kim, Jin Young Kim, Young Rok Do, Keon Uk Park, Hong Suk Song, Ki Young Kwon, Min Kyung Kim, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Hwak Kim, Sang Kyun Sohn
Cancer Res Treat. 2013;45(2):112-117.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.112
AbstractAbstract PDFPubReaderePub
PURPOSE
We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
MATERIALS AND METHODS
A total of 567 consecutive patients with newly diagnosed DLBCL treated with rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included in the current study. All of the patients underwent a BM study at the initial staging and the clinical characteristics and prognosis of these patients with or without BM involvement were analyzed retrospectively.
RESULTS
The total cohort included 567 patients. The overall incidence of BM involvement was 8.5%. With a median follow-up duration of 33.2 months (range, 0.1 to 80.7 months) for patients who were alive at the last follow-up, the five-year overall survival (OS) and event-free survival (EFS) rate in patients without BM involvement (76.3% and 67.5%, p<0.001) was statistically higher than that in patients with BM involvement (44.3% and 40.1%, p<0.001). In multivariate analysis, among total patients, BM involvement showed a significant association with OS and EFS. In univariate and multivariate analyses, even among stage IV patients, a significant association with worse EFS was observed in the BM involvement group.
CONCLUSION
BM involvement at diagnosis affected the survival of patients with DLBCL who received RCHOP. Although use of RCHOP can result in significant improvement of the therapeutic effect of DLBCL, BM involvement is still a negative prognostic factor of DLBCL patients in the era of rituximab.

Citations

Citations to this article as recorded by  
  • Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
    Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Eri Kawata, Hitoji Uchiyama, Junya Kuroda
    Diagnostics.2021; 11(9): 1724.     CrossRef
  • Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
    Jeffrey W. Craig, Michael J. Mina, Jennifer L. Crombie, Ann S. LaCasce, David M. Weinstock, Geraldine S. Pinkus, Olga Pozdnyakova, Francesco Bertolini
    PLOS ONE.2018; 13(7): e0199708.     CrossRef
  • HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era
    Maria Joao Baptista, Olga Garcia, Mireia Morgades, Eva Gonzalez-Barca, Pilar Miralles, Armando Lopez-Guillermo, Eugenia Abella, Miriam Moreno, Juan-Manuel Sancho, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
    AIDS.2015; 29(7): 811.     CrossRef
  • Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
    José Carlos Jaime-Pérez, Carmen Magdalena Gamboa-Alonso, Alberto Vázquez-Mellado de Larracoechea, Marisol Rodríguez-Martínez, César Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer
    Archives of Medical Research.2015; 46(6): 454.     CrossRef
  • 24,984 View
  • 63 Download
  • 4 Crossref
Close layer
Metachronous Double Primary Cancer after Diagnosis of Gastric Cancer
Jin Young Kim, Won Young Jang, Mi Hwa Heo, Kang Kuk Lee, Young Rok Do, Keon Uk Park, Hong Suk Song, Yoon Nyun Kim
Cancer Res Treat. 2012;44(3):173-178.   Published online September 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.3.173
AbstractAbstract PDFPubReaderePub
PURPOSE
The pattern of double primary cancers after treatment for gastric cancer is important for a patient's survival.
MATERIALS AND METHODS
We analyzed the clinicopathologic data of 214 gastric cancer patients from October 1996 to November 2007 with regard to metachronous second primary cancers.
RESULTS
Out of 5,778 patients with gastric cancer, metachronous second primary cancers occurred in 214 patients. The median age was 61.8 years, the number of male and female patients was 140 (65.4%), 74 (34.6%), respectively. The median time to the occurrence of second cancers after diagnosis of the first was 39.2 months (standard deviation, 31.2 months). The most common cancer was colorectal cancer, which occurred in 44 patients (20.6%), and lung cancer in 33 patients (15.4%), hepatocellular carcinoma in 26 patients (12.1%), ovarian cancer in 15 patients (7.0%), cervical cancer in 12 patients (7.0%), breast cancer in 11 patients (5.1%), and esophageal cancer in 11 patients (5.1%). The observed/expected (O/E) ratio showed a significant increase in colorectal (1.25), male biliary (1.60), ovarian (8.72), and cervical cancer (3.33) with primary gastric cancer. After five years from diagnosis of gastric cancer, secondary cancer occurred in 50 patients (23.4%), and breast cancer, prostate cancer, laryngeal cancer, lung cancer, and hepatocellular carcinoma were the most frequent.
CONCLUSION
The O/E ratio showed a significant increase in colorectal, male biliary, ovarian, and cervical cancer with primary gastric cancer, and second primary cancer as the main cause of death for these patients. A follow-up examination for metachronous double primary cancer is needed in order to improve the survival time in patients with gastric cancer.

Citations

Citations to this article as recorded by  
  • Gastric Metastasis Mimicking Early Gastric Cancer from Invasive Ductal Carcinoma of the Breast: Case Report and Literature Review
    Kwon Cheol Yoo, Dae Hoon Kim, Sungmin Park, HyoYung Yun, Dong Hee Ryu, Jisun Lee, Seung-Myoung Son
    Medicina.2024; 60(6): 980.     CrossRef
  • Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature
    Makiko So, Aya Shimoji, Yoko Iemura, Ai Suizu, Shuichiro Iwami, Masahito Hoki, Shinsuke Shibuya
    International Cancer Conference Journal.2024; 13(4): 427.     CrossRef
  • Incidence and pattern of second primary cancer in patients diagnosed with primary cancer
    Jong Sung, Ae Ahn, Ho Park, Kyu Jang, Woo Moon, Ju-Hyung Lee, Kyoung Kim, Myoung Chung
    Oncology Letters.2024;[Epub]     CrossRef
  • The risk and distribution of second primary cancers according to subsite of primary stomach cancer: a retrospective cohort population-based study
    Ali Hemade, Souheil Hallit
    Annals of Medicine & Surgery.2024; 86(12): 6944.     CrossRef
  • Features of synchronous and metachronous dual primary gastric and colorectal cancer
    Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
    World Journal of Gastrointestinal Oncology.2023; 15(11): 1864.     CrossRef
  • Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea
    Jeong Ho Song, Yeonkyoung Lee, Jaesung Heo, Sang-Yong Son, Hoon Hur, Sang-Uk Han
    Cancers.2022; 14(24): 6165.     CrossRef
  • Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report
    Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • The contribution of second primary cancers to the mortality of patients with a gastric first primary cancer
    Samantha Morais, Luís Antunes, Maria J. Bento, Nuno Lunet
    European Journal of Gastroenterology & Hepatology.2019; 31(4): 471.     CrossRef
  • Second Primary Cancer after Treating Gastrointestinal Cancer
    Jeong Youp Park
    The Korean Journal of Gastroenterology.2019; 74(4): 193.     CrossRef
  • Gastric cancer and intrahepatic cholangiocarcinoma
    Alex Emmanuel Elobu, Ashok Thorat, Vianney Kweyamba, Rakesh Rai
    Formosan Journal of Surgery.2019; 52(3): 107.     CrossRef
  • Occurrence of metachronous multiple primary cancers occurred in different parts of the stomach with 2 pathologic features
    Yan Song, Ningning Zhao, Kui Jiang, Zhongqing Zheng, Bangmao Wang, Dalu Kong, Shu Li
    Medicine.2018; 97(20): e10803.     CrossRef
  • Surgical Strategy and Outcome in Patients Undergoing Pancreaticoduodenectomy After Gastric Resection: A Three‐Center Experience with 39 Patients
    Dooin Lee, Jae Hoon Lee, Dongho Choi, Chang Moo Kang, Jae Uk Chong, Song‐Chul Kim, Kyeong Geun Lee
    World Journal of Surgery.2017; 41(2): 552.     CrossRef
  • Risk of second primary cancers among patients with a first primary gastric cancer: A population-based study in North Portugal
    Samantha Morais, Luís Antunes, Maria José Bento, Nuno Lunet
    Cancer Epidemiology.2017; 50: 85.     CrossRef
  • Incidence of Gastric Cancer in Patients with Laryngeal Cancer
    Ji-Hyun Seo, Hyun-Jin Kim, Jung Je Park, Ok-Jae Lee, Jin Pyeong Kim, Seong-Ki Ahn, Jeong Seok Hwa, Jong Sil Lee, Hee-Shang Youn
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(4): 190.     CrossRef
  • Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan
    San-Chi Chen, Chia-Jen Liu, Yu-Wen Hu, Chiu-Mei Yeh, Li-Yu Hu, Yen-Po Wang, Yi-Ping Hung, Cheng-Hwai Tzeng, Tzeon-Jye Chiou, Tzeng-Ji Chen, Chung-Jen Teng
    Gastric Cancer.2016; 19(2): 490.     CrossRef
  • Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan
    Yi-Ping Hung, Chia-Jen Liu, Yu-Wen Hu, Min-Huang Chen, Chun-Pin Li, Chiu-Mei Yeh, Tzeon-Jye Chiou, Tzeng-Ji Chen, Muh-Hwa Yang, Yee Chao
    Medicine.2015; 94(38): e1626.     CrossRef
  • Role of Ki‐67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease
    H. C. Miller, P. Drymousis, R. Flora, R. Goldin, D. Spalding, A. Frilling
    World Journal of Surgery.2014; 38(6): 1353.     CrossRef
  • Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
    Chan Kim, Hong Jae Chon, Beodeul Kang, Kiyeol Kim, Hei-Cheul Jeung, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
    BMC Cancer.2013;[Epub]     CrossRef
  • 11,747 View
  • 89 Download
  • 18 Crossref
Close layer
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
Cancer Res Treat. 2009;41(1):12-18.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.12
AbstractAbstract PDFPubReaderePub
Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
    Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
    Chemical Physics Letters.2024; 842: 141191.     CrossRef
  • Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
    S. Shruthi, K. Bhasker Shenoy
    ChemistrySelect.2024;[Epub]     CrossRef
  • Recent Advances on Pt-Based Compounds for Theranostic Applications
    Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
    Molecules.2024; 29(15): 3453.     CrossRef
  • Hallmarks of anticancer and antimicrobial activities of corroles
    Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
    Drug Resistance Updates.2023; : 100931.     CrossRef
  • Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
    Dobrina Tsvetkova, Stefka Ivanova
    Molecules.2022; 27(8): 2466.     CrossRef
  • Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
    Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
    Coordination Chemistry Reviews.2022; 472: 214790.     CrossRef
  • Metalofármacos en la terapia contra el cáncer
    Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
    TECNOCIENCIA Chihuahua.2022; 16(3): e1010.     CrossRef
  • Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Dan Gibson
    Journal of Inorganic Biochemistry.2021; 217: 111353.     CrossRef
  • Monofunctional Platinum(II) Anticancer Agents
    Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
    Pharmaceuticals.2021; 14(2): 133.     CrossRef
  • Pt(IV) Prodrugs with NSAIDs as Axial Ligands
    Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
    International Journal of Molecular Sciences.2021; 22(8): 3817.     CrossRef
  • Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Dan Gibson
    Journal of Inorganic Biochemistry.2019; 191: 77.     CrossRef
  • TOXview: a novel graphical presentation of cancer treatment toxicity profiles
    Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Acta Oncologica.2019; 58(8): 1138.     CrossRef
  • Photoactivated platinum-based anticancer drugs
    Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
    Coordination Chemistry Reviews.2018; 376: 405.     CrossRef
  • Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
    Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
    Cancer Chemotherapy and Pharmacology.2018; 81(6): 981.     CrossRef
  • An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
    Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
    Management Science.2016; 62(5): 1511.     CrossRef
  • Platinum(iv) anticancer prodrugs – hypotheses and facts
    Dan Gibson
    Dalton Transactions.2016; 45(33): 12983.     CrossRef
  • Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
    Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
    Journal of Inorganic Biochemistry.2016; 162: 109.     CrossRef
  • VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
    Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
    Molecular Pharmaceutics.2016; 13(11): 3712.     CrossRef
  • Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
    Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
    AIP Advances.2014;[Epub]     CrossRef
  • Nanocarriers for delivery of platinum anticancer drugs
    Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
    Advanced Drug Delivery Reviews.2013; 65(13-14): 1667.     CrossRef
  • Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
    Investigational New Drugs.2012; 30(3): 1224.     CrossRef
  • Cellular interactions of platinum drugs
    Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
    Inorganica Chimica Acta.2012; 393: 75.     CrossRef
  • What do we know about the reduction of Pt(IV) pro-drugs?
    Ezequiel Wexselblatt, Dan Gibson
    Journal of Inorganic Biochemistry.2012; 117: 220.     CrossRef
  • Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
    X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
    European Journal of Surgical Oncology (EJSO).2011; 37(6): 466.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • 12,123 View
  • 114 Download
  • 26 Crossref
Close layer
Prognostic Significance of Immunohistochemical Expression of p53 Gene Product in Operable Breast Cancer
Hong Suk Song, Young Rok Do, Sun Hee Kang, Ki Yong Jeong, Yu Sa Kim
Cancer Res Treat. 2006;38(4):218-223.   Published online December 31, 2006
DOI: https://doi.org/10.4143/crt.2006.38.4.218
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to investigate the prognostic significance of the expression of p53 gene product in operable invasive breast cancer by performing immunohistochemical analysis.

Materials and Methods

Between January 1993 and December 2001, 440 operable invasive breast cancer patients underwent immunohistochemical staining for p53, and we retrospectively analyzed these results together with the clinical outcomes.

Results

The overexpression of p53 was detected in 51.6% of the cases. The overexpression of p53 was inversely correlated with lymph node metastasis (p=0.005). The tumor size, tumor histology, histologic grade, hormonal receptor status and tumor stage were not related to the overexpression of p53. Multivariate Cox regression analysis indicate that lymph node metastasis, tumor size and the p53 expression were the significant prognostic factors for overall survival; lymph node metastasis, the estrogen receptor status and the p53 expression were the significant prognostic factors for relapse free survival. On the subgroup analysis, the p53 non-expressors showed better 7-year overall survival (92.7% vs. 76.7%, respectively, p=0.011) and relapse free survival (74.9% vs. 57.8%, respectively, p=0.032) than did the p53 overexpressors for the patients with lymph node metastasis. However, for the patients without lymph node metastasis, the survival rates were not different for both the p53 non-expressors and the p53 overexpressors.

Conclusion

Immunohistochemical staining of the p53 gene product was an independent prognostic factor for predicting survival of the lymph node positive invasive breast cancer patients.

Citations

Citations to this article as recorded by  
  • Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases
    Amber N. Hurson, Mustapha Abubakar, Alina M. Hamilton, Kathleen Conway, Katherine A. Hoadley, Michael I. Love, Andrew F. Olshan, Charles M. Perou, Montserrat Garcia-Closas, Melissa A. Troester
    npj Breast Cancer.2022;[Epub]     CrossRef
  • Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases
    PalashKumar Mandal, Anindya Adhikari, Subir Biswas, Amita Giri, Arnab Gupta, Arindam Bhattacharya
    Cancer Translational Medicine.2020; 6(2): 30.     CrossRef
  • Evaluation of p53 in breast cancer and its correlation with various histological prognostic factors
    Kriti Arora, Ruchee Khandelwal, Hema Pant
    Indian Journal of Pathology and Oncology.2020; 7(3): 392.     CrossRef
  • Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients
    Rahmawati Pare, Patsy S. Soon, Aashit Shah, Cheok Soon Lee, Aamir Ahmad
    PLOS ONE.2019; 14(4): e0214604.     CrossRef
  • Immunohistochemical expression levels of p53 and eIF4E markers in histologically negative surgical margins, and their association with the clinical outcome of patients with head and neck squamous cell carcinoma
    JAGTAR SINGH, RAMA JAYARAJ, SIDDHARTHA BAXI, MARIANA MILEVA, JOHN SKINNER, NAVNEET K. DHAND, MAHIBAN THOMAS
    Molecular and Clinical Oncology.2016; 4(2): 166.     CrossRef
  • Updated overview of current biomarkers in head and neck carcinoma
    Kiran Dahiya, Rakesh Dhankhar
    World Journal of Methodology.2016; 6(1): 77.     CrossRef
  • Evaluation of p53, HoxD10, and E-Cadherin Status in Breast Cancer and Correlation with Histological Grade and Other Prognostic Factors
    Preethi Sekar, Jyotsna Naresh Bharti, Jitendra Singh Nigam, Ankit Sharma, Priyanka Bhatia Soni
    Journal of Oncology.2014; 2014: 1.     CrossRef
  • An Australian Retrospective Study to Evaluate the Prognostic Role of p53 and eIF4E Cancer Markers in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): Study Protocol
    Jagtar Singh, Rama Jayaraj, Siddhartha Baxi, Mariana Mileva, Justin Curtin, Mahiban Thomas
    Asian Pacific Journal of Cancer Prevention.2013; 14(8): 4717.     CrossRef
  • Morphometric and Histological Study of Breast Lesions with Special Reference to Proliferative Activity and Invasiveness
    Asim Kumar Manna, Aparajita Samaddar, Sumit Mitra, Swapan Pathak, Srabani Chakrabarti, Diptendra Kumar Sarkar
    Indian Journal of Surgery.2013; 75(3): 204.     CrossRef
  • Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients
    Mais M Al-Mumen, Asad A Al-Janabi, Alaa S Jumaa, Kaswer M Al-Toriahi, Akeel A Yasseen
    BMC Research Notes.2011;[Epub]     CrossRef
  • Balance between SIRT1 and DBC1 expression is lost in breast cancer
    Ji‐Youn Sung, Ranah Kim, Ja‐Eun Kim, Juhie Lee
    Cancer Science.2010; 101(7): 1738.     CrossRef
  • 9,362 View
  • 89 Download
  • 11 Crossref
Close layer
A Multi-Center, Phase II Clinical Trial of Padexol™ (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer
Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Young Rok Do, Hong Suk Song, Won Sik Lee, Keon Uk Park, Jin Ho Baek, Jong Gwang Kim
Cancer Res Treat. 2005;37(6):349-353.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.349
AbstractAbstract PDFPubReaderePub
Purpose

We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma.

Materials and Methods

39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m2 was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 as an intravenous infusion on day 1, once every 3 weeks.

Results

Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild.

Conclusion

The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Effect of the Weekly Administration of Liposome–Paclitaxel Combined with S-1 on Advanced Gastric Cancer
    Lei Chen, Qiang Chen, Zhixiang Zhuang, Yusong Zhang, Jialong Tao, Liqin Shen, Xudong Shen, Zhigang Chen, Ji Wang, Minggao Zhu, Hui Wang
    Japanese Journal of Clinical Oncology.2014; 44(3): 208.     CrossRef
  • Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
    Jin Young Kim, Young Rok Do, Keon Uk Park, Jong Gwang Kim, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Hun Mo Ryoo, Sung Hwa Bae, Jin Ho Baek, Hong Suk Song
    Cancer Chemotherapy and Pharmacology.2011; 67(3): 527.     CrossRef
  • Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
    Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Kazuma Okamoto, Eigo Otsuji, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Tetsuro Yamashita, Fumihiro Taniguchi, Hideki Aragane, Hiroshi Nishi, Yoshiki Itokawa, Satoshi Morita, Junichi Sak
    Gastric Cancer.2010; 13(3): 149.     CrossRef
  • TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
    Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Won Sik Lee, Chang-Hak Sohn, Joo Seop Jung, Gab Chul Kim, Ho Young Chung, Wansik Yu
    Cancer Chemotherapy and Pharmacology.2009; 64(2): 355.     CrossRef
  • Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
    Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
    Japanese Journal of Clinical Oncology.2009; 39(4): 237.     CrossRef
  • A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
    Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
    Cancer Research and Treatment.2007; 39(1): 6.     CrossRef
  • Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
    Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wan
    Cancer Chemotherapy and Pharmacology.2007; 60(6): 863.     CrossRef
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 10,258 View
  • 72 Download
  • 8 Crossref
Close layer
Prognostic Significance of Immunohistochemical Expression of EGFR and C-erbB-2 Oncoprotein in Curatively Resected Gastric Cancer
Hong Suk Song, Young Rok Do, In Ho Kim, Soo Sang Sohn, Kun Young Kwon
Cancer Res Treat. 2004;36(4):240-245.   Published online August 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.4.240
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study was to investigate the prognostic significance of the expression of EGFR and C-erbB-2 gene products by immunohistochemical analysis for curatively resected gastric adenocarcinoma.

Materials and Methods

Between January 1996 and December 2001, 739 patients with curatively resected gastric cancer patients underwent immunohistochemical staining for EGFR and C-erbB-2 proteins, and we retrospectively analyzed their correlation with the clinical outcome.

Results

The overexpressions of EGFR and C-erbB-2 were 25.4% and 26.2%, respectively. The overexpressions of EGFR was associated with the more poorly differentiated tumor (p=0.000) and with neuronal invasion (p=0.03). Overexpression of C-erbB-2 was associated with less vascular invasion (p=0.001). Tumor depth or node metastasis was not related to the overexpression of EGFR or C-erbB-2. The seven-year overall survival and relapse-free survival rates were 87.2% and 75.8%, respectively. Upon multivariate Cox regression analysis, the tumor stage, tumor size and patient age were important prognostic factors for overall survival, and tumor stage was the important factor for relapse-free survival. Overexpressions of EGFR or c-erbB-2 were not significant prognostic factors.

Conclusion

Immunohistochemical staining of EGFR and C-erbB-2 gene products were not independent prognostic factors for predicting the overall survival and the relapse-free survival in curatively resected gastric cancer.

Citations

Citations to this article as recorded by  
  • GRB7-mediated enhancement of cell malignant characteristics induced by Helicobacter pylori infection
    Huilin Zhao, Si Chen, Xinfeng Bai, Jianhui Zhang, Shuzhen Liu, Zekun Sun, Xinying Cao, Jianping Wang, Ying Zhang, Boqing Li, Xiaofei Ji
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Human epidermal growth factor receptor-2 gene expression positivity determined by silver in situ hybridization/immunohistochemistry methods and associated factors in a cohort of Sri Lankan patients with gastric adenocarcinoma: a prospective study
    Duminda Subasinghe, Nathan Acott, Pasyodun Koralage Buddhika Mahesh, Sivasuriya Sivaganesh, Sithum Munasinghe, Mariyan Priyanthi Kumarasinghe, Dharmabandu Nandaveva Samarasekera, Menaka Dilani Samarawickrema Lokuhetty
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Deep muscularis propria tumor invasion without lymph node metastasis as a unique subclassification of stage IB gastric cancer: a retrospective study
    Kang He, Cheng Chen, Lei Xia, Lixiang Si, Xiaohua Pan, Zijian Sun, Yajing Wang, Yingying Jiang, Yue Shi, Bin Zhou, Shuaiyu Wang, Jing Han, Bo Shen, Guoren Zhou, Jianwei Lu, Xiaohua Wang
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Expression of HER2/c-erbB-2, EGFR protein in gastric carcinoma and its clinical significance
    Guoxiong Cheng, Yijun Mei, Xiaoming Pan, Ming Liu, Suping Wu
    Open Life Sciences.2019; 14(1): 119.     CrossRef
  • An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis
    Y. Wang, L. He, Y. Cheng
    Clinical and Translational Oncology.2018; 20(2): 212.     CrossRef
  • IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules
    Nikolaos A. Afratis, Panagiotis Bouris, Spyros S. Skandalis, Hinke A. Multhaupt, John R. Couchman, Achilleas D. Theocharis, Nikos K. Karamanos
    Scientific Reports.2017;[Epub]     CrossRef
  • The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
    Yu-ying Lei, Jin-yu Huang, Qiong-rui Zhao, Nan Jiang, Hui-mian Xu, Zhen-ning Wang, Hai-qing Li, Shi-bo Zhang, Zhe Sun
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas
    Aleksandra Paliga, Horia Marginean, Basile Tessier-Cloutier, Bibianna Purgina, Derek Jonker, Esmeralda C. Marginean
    American Journal of Clinical Oncology.2017; 40(6): 543.     CrossRef
  • Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis
    Zhiqiao Zhang, Hongfeng Tang, Jixin Lin, Yunzhao Hu, Guanying Luo, Zhaowen Luo, Canchang Cheng, Peng Wang
    Oncotarget.2017; 8(10): 17202.     CrossRef
  • Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma
    Roberto de Moraes Cordts Filho, Paulo Kassab, Laura Carolina Lopez Claro, Mabel Tatty de Medeiros Fracassi, Patrícia Colombo-Souza, Daniel Kenji Fukuhara, Fábio Rodrigues Thuler, Wilson Rodrigues de Freitas Junior, Elias Jirjoss Ilias, Carlos Alberto Malh
    The Scientific World Journal.2016; 2016: 1.     CrossRef
  • The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR
    Ghasem Janbabai, Ziaeddin Oladi, Touraj Farazmandfar, Tarang Taghvaei, Farshad Naghshvar
    Journal of Cancer Research and Clinical Oncology.2015; 141(11): 1945.     CrossRef
  • The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines
    Darren Chyi-Hsiang Kong, Kenneth Yee Chew, Eng Tan, Suan Khoo
    Cancer Cell International.2014; 14(1): 65.     CrossRef
  • Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study
    K. AYDIN, S.K. OKUTUR, M. BOZKURT, I. TURKMEN, E. NAMAL, K. PILANCI, A. OZTURK, Z. AKCALI, G. DOGUSOY, O.G. DEMIR
    Oncology Letters.2014; 7(1): 255.     CrossRef
  • Metastatic gastric cancer treatment: a little slow but worthy progress
    Ozkan Kanat, Bert H. O’Neil
    Medical Oncology.2013;[Epub]     CrossRef
  • Advanced HER2-positive gastric cancer: Current and future targeted therapies
    Roberto A. Pazo Cid, Antonio Antón
    Critical Reviews in Oncology/Hematology.2013; 85(3): 350.     CrossRef
  • The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
    Akin Atmaca, Dominique Werner, Claudia Pauligk, Kristina Steinmetz, Ralph Wirtz, Hans-Michael Altmannsberger, Elke Jäger, Salah-Eddin Al-Batran
    BMC Cancer.2012;[Epub]     CrossRef
  • Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review
    Terence C. Chua, Neil D. Merrett
    International Journal of Cancer.2012; 130(12): 2845.     CrossRef
  • Bioinformatics analysis with graph-based clustering to detect gastric cancer-related pathways
    P. Liu, X. Wang, C.H. Hu, T.H. Hu
    Genetics and Molecular Research.2012; 11(3): 3497.     CrossRef
  • Evolving Standards of Care in Advanced Gastric Cancer
    Jean-Emmanuel Kurtz, Patrick Dufour
    Future Oncology.2011; 7(12): 1441.     CrossRef
  • 10,368 View
  • 63 Download
  • 19 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP